• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer

    1/6/25 8:00:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RXRX alert in real time by email

    Dr. Secora is formerly the CFO and Executive Leader of Value Translation at Recursion

    Iambic Therapeutics, a clinical-stage biotechnology company developing novel medicines using its AI-driven discovery and development platform, announced that Michael Secora, Ph.D. will be its Chief Corporate Development Officer and Chief Financial Officer. Dr Secora will lead Iambic's finance and corporate development activities, helping frame its growing pipeline and industry-leading platform to potential partners, investors, and other stakeholders.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250106188573/en/

    Michael Secora, PhD, Chief Corporate Development Officer and Chief Financial Officer, Iambic Therapeutics (Photo: Business Wire)

    Michael Secora, PhD, Chief Corporate Development Officer and Chief Financial Officer, Iambic Therapeutics (Photo: Business Wire)

    "Michael is a unique and effective leader with experience as a scientist, investor, and operator. He has demonstrated strategic and tactical success leading both scientific and technical teams as well as business-related and capital raising efforts," said Tom Miller, Ph.D., Co-Founder and CEO of Iambic. "More importantly, Michael is passionate about the increased inclusion of technology within the life sciences to transform drug discovery and development. We are excited to welcome Michael to Iambic and look forward to driving our scientific and business objectives forward together."

    For over a decade, Dr. Secora has been a leader in defining the value proposition for technology-driven drug development, drawing on his scientific, capital markets and business expertise. At Recursion (NASDAQ:RXRX), he led finance, communications, and investor relations activities as well as corporate strategy for translating value both internally and externally across Recursion's internal pipeline, external partnerships, and data. Dr. Secora led efforts related to Recursion's entering collaborations with Bayer, Roche-Genentech, NVIDIA, Google, Tempus, and others; combining with Exscientia (EXAI), Cyclica, Valence, and Vium; and raising over $1.3 billion for Recursion across both private and public fundraising rounds.

    "There are many things that I am excited about at Iambic. First, committed leadership - I admire how Tom and Fred left their professorships at Caltech and Bristol to found and lead Iambic. Second, experimental platform - I am impressed with the integration and automation of chemical synthesis, mass spectrometry, target and pathway deconvolution, and data flow optimization. Third, AI-technology - I believe that Iambic's expertise in active learning and multimodal transformer models has created industry-leading computational tools. Lastly, clinical pipeline advancement - Iambic has demonstrated an ability to go from beginning a program to a Phase 1 clinical trial in approximately 2 years, which is extraordinarily fast," said Dr. Secora.

    Iambic's pipeline includes IAM1363, a potential best-in-class, highly selective and brain penetrant small molecule inhibitor of both wild-type and oncogenic HER2 mutants currently in a Phase 1 study with data anticipated in 2025, as well as a potential first-in-class selective dual CDK2/4 inhibitor for multiple cancer indications, an allosteric inhibitor for KIF18A, and additional new programs.

    Dr. Secora went on to say, "I have been impressed with Iambic's development over the last few years as well as the strength of Iambic's board, scientific advisors, and partners. As a scientist and investor, I believe in the increasing inclusion of technology into many aspects of our way of life. As a leader, I choose to serve organizations that have the potential for substantial and long-term positive impact. I see Iambic having such an impact in the life science and technology industries now and into the future."

    Prior to Recursion, Dr. Secora had a successful 10-year investing career at Laurion Capital as Managing Director and Head of Capital Markets and Venture, where he focused on emerging technologies and the life sciences and was an early advocate and investor in the TechBio space. Dr. Secora is an alumnus of Princeton University with a doctorate in Applied and Computational Mathematics and has undergraduate degrees in Mathematics and Physics and minor degrees in Astronomy and Writing and Humanistic Studies from the Massachusetts Institute of Technology (MIT).

    About Iambic's AI-Driven Discovery Platform

    The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures. The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence.

    About Iambic Therapeutics

    Founded in 2019 and headquartered in San Diego, California, Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to the clinical stage with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250106188573/en/

    Get the next $RXRX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RXRX

    DatePrice TargetRatingAnalyst
    7/3/2025$5.00Equal-Weight
    Morgan Stanley
    5/22/2023$8.00Equal-Weight
    Morgan Stanley
    3/16/2023$17.00Buy
    Needham
    9/16/2022$20.00Overweight
    KeyBanc Capital Markets
    4/18/2022$10.00Buy → Neutral
    BofA Securities
    3/4/2022$32.00 → $10.00Outperform → Market Perform
    SVB Leerink
    12/8/2021$30.00 → $32.00Outperform
    SVB Leerink
    9/21/2021$37.00Buy
    Berenberg
    More analyst ratings

    $RXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Li Dean Y was granted 1,949 shares, increasing direct ownership by 0.16% to 1,236,567 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      7/3/25 3:30:26 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Dar Zavain was granted 2,924 shares, increasing direct ownership by 2% to 135,817 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      7/3/25 3:30:17 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Borgeson Blake was granted 22,016 shares, increasing direct ownership by 0.31% to 7,089,863 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      6/23/25 5:23:44 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RXRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

      Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder. "We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage," said David Hallett, Chief Scientific Officer of Recursion. "Having full ownership of this important program allows Recursion to accelerate the development of the first

      7/8/25 8:00:00 AM ET
      $RLYB
      $RXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway

      Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- Several experts are seeing that value of AI's total overhaul of healthcare, including beneficial additions such as generative AI apps demonstrating real value. The next wave of AI's healthcare transformation is already taking shape—led by intelligent agents, next-gen diagnostics, and predictive drug discovery platforms. Behind the scenes, a new class of innovators is making tangible progress, with companies like Avant Technologies, Inc. (OTCQB:AVAI), Tempus Ai, Inc. (NASDAQ:TEM), OmniAb, Inc. (NASDAQ:OABI), Tevogen Bio Holdings Inc. (NASDAQ:TVGN), and Recursion Pharmaceutic

      6/30/25 9:50:00 AM ET
      $OABI
      $RXRX
      $TEM
      $TVGN
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Computer Software: Programming Data Processing
    • MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

      Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but at speeds up to 1000x faster in standard benchmarks The development of this open source model for academic and commercial use was a collaborative effort, combining MIT's deep academic expertise with Recursion's AI research and NVIDIA-accelerated supercomputer, BioHive-2 Salt Lake City, UT, June 06, 2025 (GLOBE NEWSWIRE) -- Researchers at the Massachusetts Institute of Technology (MIT) Computer Science and Artificial Intelligence Lab (CSAIL) and Jameel Clinic, alongside TechBio company

      6/6/25 10:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RXRX
    SEC Filings

    See more
    • Recursion Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Unregistered Sales of Equity Securities

      8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      7/8/25 8:19:11 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B7 filed by Recursion Pharmaceuticals Inc.

      424B7 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      7/8/25 8:14:08 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      6/18/25 4:22:09 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley resumed coverage on Recursion Pharmaceuticals with a new price target

      Morgan Stanley resumed coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $5.00

      7/3/25 7:50:07 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley initiated coverage on Recursion Pharmaceuticals with a new price target

      Morgan Stanley initiated coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $8.00

      5/22/23 7:50:41 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Needham initiated coverage on Recursion Pharmaceuticals with a new price target

      Needham initiated coverage of Recursion Pharmaceuticals with a rating of Buy and set a new price target of $17.00

      3/16/23 9:18:01 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RXRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

      Salt Lake City, UT, March 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé Bumpus, Ph.D, and Elaine Sun have been appointed to Recursion's Board of Directors, effective as of March 15th."I am delighted to welcome Elaine and Namandjé to Recursion's Board," said Chris Gibson, Ph.D., Recursion Co-Founder and CEO. "As the company continues to grow its clinical pipeline and enhance its platform, our new Board members' scientific, clinical, business and financial expertise will be an incredible resource in support of our continued success."Dr. Namandjé N. Bumpus served as the

      3/18/25 8:00:00 AM ET
      $DVAX
      $RXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Altitude Lab Startups Raise $154M in Capital

      SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Today, Altitude Lab announced that its incubating startups have collectively raised $154 million in early-stage funding since its launch in 2020. Founded by Recursion, Altitude Lab supports diverse life science entrepreneurs in Utah by providing fully equipped laboratories, access to investors, business operations education, and a collaborative founder community.In addition, Altitude Lab awarded its inaugural Gibson Founder Fellowship to Carmen Kivisild, Ph.D., CEO and founder of Elnora AI. The fellowship provides early-career scientists with up to $150,000 in funding, scientific support, and mentorship to accelerate the growth of their sta

      2/18/25 11:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer

      Dr. Secora is formerly the CFO and Executive Leader of Value Translation at Recursion Iambic Therapeutics, a clinical-stage biotechnology company developing novel medicines using its AI-driven discovery and development platform, announced that Michael Secora, Ph.D. will be its Chief Corporate Development Officer and Chief Financial Officer. Dr Secora will lead Iambic's finance and corporate development activities, helping frame its growing pipeline and industry-leading platform to potential partners, investors, and other stakeholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250106188573/en/Michael Secora, PhD, Chief Cor

      1/6/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RXRX
    Financials

    Live finance-specific insights

    See more
    • Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

      Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder. "We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage," said David Hallett, Chief Scientific Officer of Recursion. "Having full ownership of this important program allows Recursion to accelerate the development of the first

      7/8/25 8:00:00 AM ET
      $RLYB
      $RXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

      Salt Lake City, UT, April 28, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2025 financial results on Monday, May 5, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on May 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/LYZwaVdPJidC7x259. Abo

      4/28/25 8:27:07 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

      Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on February 28, 2025 at 8:30 am ET / 6:30 am MT / 1:30 pm GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://bit

      2/24/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      11/12/24 4:57:06 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      11/12/24 10:34:18 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      11/4/24 4:16:21 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care